Antibiotic Development Question: Should A Phage Library Equal One Application?
Executive Summary
FDA may have to take a personalized medicine approach when deciding how to classify a phage bank used to create the treatments.
You may also be interested in...
Antibiotic Guidance: Limited Populations Do Not Include Rare Infections
US FDA draft guidance on Limited Population Antibacterial Drug pathway says eligibility considerations for preventative products will center on size of population receiving drug, not incidence of infection.
Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement
US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.
BiomX Wants To Reverse The Focus Of Microbiome Therapy
Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.